Hexarelin Peptide: Research Overview, Purity Data and Where to Buy

Hexarelin is one of the few growth hormone secretagogues in the published literature that doesn't act through a single receptor. Alongside activity at the ghrelin receptor, research describes binding at CD36, a scavenger receptor expressed densely in cardiac and vascular tissue, which is why a large share of Hexarelin papers sit in cardiovascular journals rather than endocrinology ones.

Real Peptides supplies research-use-only peptides and publishes lot certificates of analysis at /coas/. They're about lot traceability, molecular identity confirmation, and cold chain integrity. All products are sold for laboratory research use only and are not for human consumption.

What is Hexarelin?

Hexarelin, also catalogued as examorelin, is a synthetic hexapeptide growth hormone secretagogue with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 and a molecular weight of roughly 887 g/mol. The literature describes it as a GHS-R1a agonist that also binds the scavenger receptor CD36. It ships as a lyophilized powder for laboratory research.

The common oversimplification is that Hexarelin is just a stronger version of the earlier growth hormone-releasing peptides. Receptor potency is only part of the picture, because the CD36 interaction gives Hexarelin a pharmacological footprint the older secretagogues don't fully share, and reports of receptor desensitization during repeated exposure complicate head-to-head comparisons further. This page covers the compound's class and mechanism, what published studies actually examine, laboratory handling and storage, how purity is verified per lot, regulatory status, and how researchers source it.

A hexapeptide built to survive enzymatic breakdown

Hexarelin is a synthetic six-amino-acid peptide, which is exactly where the name comes from. Its structure, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, carries two unnatural D-configuration residues and a methyl group on the tryptophan at position two, plus an amidated C-terminus. Those modifications aren't cosmetic. They're what slow enzymatic degradation relative to the native receptor ligand, and they're the reason the molecule shows a usable half-life in the animal models where it's been characterized.

The primary target described in the literature is the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor expressed in the hypothalamus and on pituitary somatotrophs. Agonism at GHS-R1a triggers a phospholipase C and inositol trisphosphate signalling cascade, raising intracellular calcium and driving growth hormone release in a pulsatile pattern rather than a flat elevation. Research also describes suppression of somatostatin tone, which is the inhibitory brake on that pulse.

The second target is where Hexarelin separates from the pack. CD36, sometimes called fatty acid translocase, is a class B scavenger receptor expressed in cardiomyocytes, macrophages and vascular endothelium. Studies report that several cardiovascular effects of Hexarelin persist in models lacking a functional GHS-R1a pathway, pointing to CD36 as an independent route of action.

Hexarelin is also described as less receptor-selective than Ipamorelin. The literature reports concurrent elevation of other pituitary hormones in some experimental settings, which matters when a study design calls for an isolated growth hormone signal.

What the published literature on this compound actually examines

The Hexarelin research record splits into three broad streams, and only one of them is endocrine. Searching the indexed literature for Hexarelin growth hormone secretagogue studies returns decades of work on pituitary signalling, somatotroph responsiveness and comparative potency against other secretagogue peptides.

The second stream is cardiovascular, and it's larger than most people expect. Work indexed under Hexarelin and cardioprotection examines ischemia-reperfusion models, ventricular function and cardiac remodelling, with several reports describing effects that appear independent of circulating growth hormone concentrations. The mechanistic bridge there is the receptor work catalogued under Hexarelin and CD36, which links the peptide to a receptor with established roles in fatty acid uptake and inflammatory signalling.

The third stream is the one researchers most often overlook. Studies report attenuation of the growth hormone response with repeated exposure, a desensitization pattern catalogued in the literature on growth hormone secretagogue receptor desensitization. That finding shapes experimental design more than any potency figure does, because a study measuring response magnitude over an extended timeline is measuring a moving target.

A practical caution on reading this body of work: much of the foundational Hexarelin literature dates from the 1990s, when it was investigated as a clinical candidate. Methods, assay sensitivity and reporting standards from that era don't always map cleanly onto current practice, and the hedged language in those abstracts is there for a reason. The information here is educational and describes published research findings, not guidance for any use outside a controlled laboratory setting.

Laboratory handling, storage and stability basics

Hexarelin arrives as a lyophilized (freeze-dried) powder, and in that state it's far more forgiving than most people assume. Research-grade lyophilized peptides are typically held at or below -20°C for long-term storage, protected from light, and kept desiccated, because residual moisture is the single biggest driver of degradation in a sealed vial. Short ambient excursions during transit are normal for lyophilized material and are not the failure point most procurement teams worry about.

The failure points that matter are different. Repeated freeze-thaw cycling fragments peptide chains, so laboratories working through a lot over weeks generally pull it from cold storage as few times as possible. Humidity ingress after a stopper has been punctured is a second one. Light exposure is a third, which is why amber vials and opaque secondary packaging exist.

Once a Hexarelin lot is in solution, stability drops sharply and the material becomes a cold chain item in the strict sense, with refrigerated handling and a short usable window. Peptide bonds hydrolyse in aqueous environments, and the tryptophan residues in the Hexarelin sequence are specifically susceptible to oxidation. Appearance tells you nothing here. A degraded solution can look identical to an intact one.

Real Peptides doesn't publish preparation instructions, and that's deliberate rather than an oversight. These are research-use-only compounds, so the only preparation-adjacent figure we supply is the mass of peptide stated on the certificate for that lot, which is the single input a laboratory needs for its own milligram-per-millilitre concentration arithmetic. Everything downstream of that number is the receiving laboratory's protocol decision.

How purity is verified before a lot ships

Purity verification for Hexarelin rests on two instruments doing two different jobs. Reverse-phase high-performance liquid chromatography (RP-HPLC) separates the target peptide from truncated sequences, deletion products and synthesis by-products, reporting the target as a percentage of total peak area. Mass spectrometry, usually electrospray ionisation or MALDI-TOF, confirms molecular identity by matching the observed mass against the theoretical mass of roughly 887 g/mol for the Hexarelin sequence. Chromatography answers how clean. Mass spectrometry answers whether it's the right molecule at all.

Here's the distinction almost nobody checks, and it's the one that causes the most confusion in procurement. HPLC purity and net peptide content are not the same measurement. HPLC purity describes the proportion of peptide material that is the correct sequence. Net peptide content describes how much of the vial's total mass is peptide at all, with the balance being counter-ions such as residual trifluoroacetic acid, bound water and salts. A lot can report high chromatographic purity while a meaningful fraction of the gross weight isn't peptide. Comparing one supplier's purity figure against another's content figure is an apples-to-oranges error, and we see it constantly.

This is why per-lot documentation beats a blanket specification sheet. A generic claim applies to a product line. A certificate of analysis applies to the specific vial in a researcher's freezer, with a lot number that ties chromatogram and spectrum to that batch. Real Peptides publishes certificates openly at realpeptides.co/coas, so a Hexarelin lot can be verified against its own analytical data rather than a marketing number.

Regulatory status and ordering Hexarelin for laboratory use

Hexarelin is not an FDA-approved drug product. It has no approved indication, it isn't a dietary supplement ingredient, and it's sold strictly as a research chemical for in vitro and laboratory investigation. Anyone describing Hexarelin as a therapy is misrepresenting its regulatory position. The World Anti-Doping Agency lists growth hormone secretagogues, Hexarelin among them, under its S2 category of prohibited substances, banned both in and out of competition.

For procurement, the verification checklist is short and worth running before any order. Confirm the CAS registry number, 140703-51-1, matches the supplier's listing. Confirm the stated molecular weight is consistent with the Hexarelin sequence. Confirm a lot-specific certificate exists and is publicly viewable rather than available on request. Confirm the supplier states research-use-only terms plainly instead of burying them in a footer.

Real Peptides manufactures in small batches with exact amino-acid sequencing and third-party analytical testing, which is a quality control model rather than a marketing posture. Small-batch synthesis means fewer vials share a single analytical record, so a certificate represents a tighter population of material. Researchers sourcing this compound can review the Hexarelin product page for the current lot's specifications, browse the wider research peptide catalog for related secretagogue and signalling compounds, or read how we define analytical standards across the line at pure peptides.

Hexarelin compared with other growth hormone secretagogues in research

The table below contrasts the compounds researchers most often evaluate alongside this one, focused on receptor target and what the published work actually investigates rather than on potency rankings.

What If: Hexarelin Sourcing and Handling Scenarios

What if a Hexarelin shipment arrives at room temperature?

Check whether the material is still a dry, intact lyophilized cake before assuming a loss. Lyophilized peptides tolerate short ambient excursions far better than solutions do, because degradation in a sealed, desiccated vial is driven primarily by moisture rather than by temperature alone. What does warrant rejection is a vial that arrives with a cracked seal, visible moisture, or a cake that has collapsed into an oily or discoloured residue.

What if the certificate of analysis has no lot number on it?

Treat it as a product specification sheet, not a certificate, and request the lot-specific document. A certificate without a lot number cannot be traced to the vial in hand, which defeats its entire purpose in a research audit trail. Genuine analytical documentation carries a batch identifier, a test date, and the actual chromatogram and mass spectrum rather than a summary line. Suppliers publishing certificates openly, as at our COA library, remove that friction entirely.

What if the observed mass doesn't match the expected molecular weight?

Stop and query the lot before it enters any experimental workflow. A mass spectrum that deviates meaningfully from the theoretical value for the Hexarelin sequence indicates either a different compound, a significant deletion sequence population, or an adduct the report hasn't accounted for. Small, predictable offsets from sodium or potassium adducts are routine and usually annotated. Unexplained deviations are not, and no purity percentage compensates for a molecular identity mismatch.

The blunt truth about research peptide purity claims

Here's the honest answer: a 99% purity claim printed on a website means nothing on its own. It isn't tied to the vial you receive, it doesn't specify whether the figure is chromatographic purity or net peptide content, and it carries no analytical evidence a reviewer could examine. The only purity data worth anything is lot-specific, dated, and published with the underlying chromatogram and spectrum attached. If a supplier can't produce that for the exact batch shipping to a laboratory, the number on the page is a marketing asset, not a quality control record. That distinction is the whole game in research peptide procurement.

Researchers evaluating this compound alongside other secretagogues can compare lot documentation across our catalog through the Hexarelin listing, the full research catalog, our published certificates of analysis, and our analytical standards at pure peptides.

What makes Hexarelin genuinely interesting as a research tool isn't its potency at the ghrelin receptor, which plenty of compounds share. It's that a single small hexapeptide reaches into two unrelated receptor systems, one endocrine and one scavenger-class, and that duality is precisely what makes clean experimental attribution so difficult. A result observed in a Hexarelin study may belong to GHS-R1a, to CD36, or to both at once, and the published work has spent thirty years trying to separate them. All products are sold for laboratory research use only and are not for human consumption.

What does Hexarelin actually do at the GHS-R1a receptor?

Hexarelin is a synthetic hexapeptide agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the G-protein-coupled receptor later shown to be the binding site for the endogenous peptide ghrelin. Activation of this receptor is generally described as Gq/11-coupled, involving phospholipase C, inositol trisphosphate generation and intracellular calcium mobilization in pituitary somatotrophs, with additional receptor expression reported in hypothalamic nuclei. Because this signaling route is separate from the growth hormone-releasing hormone receptor pathway, laboratory models often run the two in parallel to separate the contributions of each axis, and some designs add somatostatin manipulation to probe the inhibitory arm.

Secondary consequences of receptor engagement — transcriptional changes, feedback via insulin-like growth factor signaling, and receptor trafficking — are where much of the modern work sits, which is why investigators reviewing downstream signaling outcomes usually pair functional endpoints with molecular and gene expression measures. Hexarelin's selectivity profile is also part of the reason it is frequently placed beside related secretagogues when researchers compare peptide classes in experimental write-ups. Common receptor-biology questions from purchasing scientists are collected in the compound's research FAQ.

Why does Hexarelin's CD36 binding matter for cardiac research models?

Beyond GHS-R1a, Hexarelin has been described in the literature as binding CD36, a scavenger receptor expressed in cardiomyocytes, endothelium, macrophages and adipose tissue. This second binding site is one of the main reasons Hexarelin is studied separately from secretagogues that act only through the ghrelin receptor: cardiovascular endpoints can appear in models where pituitary growth hormone output is absent or suppressed, such as hypophysectomized animals and isolated perfused heart preparations. That dissociation between endocrine and cardiac effects is the specific hypothesis much of this literature was built to test.

Published preclinical work in this area has examined coronary perfusion, ischemia-reperfusion injury models, ventricular remodeling after experimental infarction and fatty acid handling in cardiac tissue. Researchers planning experiments in this direction usually start with the CD36 cardiac mechanism overview before selecting endpoints, because tissue-level readouts differ substantially from endocrine ones.

Translation between species is a persistent caveat here, and the distinction between rodent cardiac models and human clinical observations is worth reading before designing anything, as covered in the animal versus human research comparison. Mechanistic branches arising from dual-receptor binding are also summarized in the downstream effects discussion.

Who developed Hexarelin and how did it enter the scientific literature?

Hexarelin emerged from the growth hormone-releasing peptide research program that began with Bowers' work on enkephalin-derived opioid analogues in the late 1970s and 1980s, which produced GHRP-6 and its successors. Hexarelin — His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 — was developed in Europe in the early 1990s, with much of the early endocrine characterization published by Italian groups. It was designed around a methylated tryptophan residue intended to improve resistance to enzymatic degradation relative to earlier hexapeptides.

The 1996 identification of GHS-R1a and the 1999 isolation of ghrelin reframed this entire compound family: peptides that had been characterized pharmacologically for over a decade suddenly had a defined endogenous counterpart and receptor. That sequence of events explains why older Hexarelin papers describe effects empirically while later ones use receptor language.

A fuller timeline of synthesis, naming conventions and early investigational work is laid out in the peptide development history. Because naming confusion is common in catalogues, buyers often check the nomenclature explainer when matching a sequence to a label, and general background questions are collected in the Hexarelin FAQ.

What is known about Hexarelin's half-life and clearance in research models?

Hexarelin is a small, unmodified hexapeptide, and like other peptides of this size its circulating presence is short-lived relative to pegylated or fatty-acid-acylated analogues. Published pharmacokinetic work generally reports rapid distribution followed by renal and enzymatic elimination, with the biological response outlasting measurable plasma concentrations because receptor activation triggers a secretory event rather than a sustained equilibrium effect. That lag between exposure and endpoint is a recurring complication in study design, since sampling windows chosen for the parent compound will not capture the hormonal response and vice versa.

The D-amino acid substitutions and C-terminal amidation in the sequence are structural features associated with reduced susceptibility to exopeptidase cleavage compared with all-L-amino-acid analogues, which is part of why Hexarelin remains of interest as a pharmacological tool. Investigators building sampling schedules typically review the absorption, half-life and clearance summary alongside the metabolism research overview so that analytical timing matches the question being asked. Where downstream hormonal cascades rather than the parent peptide are the endpoint, the downstream effects discussion explains why those curves separate so sharply.

Which biomarkers do laboratories typically track in Hexarelin research?

Endocrine studies of growth hormone secretagogues generally rely on serial sampling rather than single time points, because the growth hormone axis is pulsatile and a single measurement says very little. Typical panels in published work include growth hormone, insulin-like growth factor 1 and IGF binding protein 3, with cortisol and prolactin frequently added because GHS-R1a agonists in this family have been examined for effects on other pituitary hormones. Glucose and insulin are often included as metabolic context.

Pulse architecture — amplitude, frequency, interpulse nadir and area under the curve — is the analytical layer that separates informative datasets from noise, and the growth hormone pulse pattern discussion explains how those parameters are derived. For labs assembling a baseline panel, the bloodwork tracking guide and the before-and-after laboratory comparison framework describe what is usually captured prior to any exposure so that drift can be distinguished from effect.

Where composition rather than hormone concentration is the endpoint, imaging or impedance measures are sequenced separately; the body composition tracking overview outlines the measurement intervals and variability issues involved.

What does preclinical research report about Hexarelin and adipose tissue?

Interest in Hexarelin and fat metabolism comes from two directions. The first is indirect: growth hormone itself is lipolytic, so any secretagogue that raises endogenous growth hormone output is expected to have downstream effects on adipose tissue, free fatty acid flux and substrate preference. The second is direct: CD36, Hexarelin's secondary binding site, is a fatty acid translocase expressed in adipocytes, which raises the possibility of receptor-level effects on lipid handling that do not depend on the pituitary at all. Published rodent work has examined both routes, and separating them experimentally requires models in which growth hormone output is controlled or absent.

Because these two mechanisms produce different time courses and different biomarker signatures, researchers evaluating endpoints usually review the fat loss mechanism and research evidence summary before selecting a measurement window, and the observed timeline discussion explains why adipose endpoints lag endocrine ones by a substantial margin in animal models. Substrate oxidation and hepatic handling questions sit in the metabolism research overview, which is the better starting point when the endpoint is energy partitioning rather than mass.

How is Hexarelin studied in muscle and body composition models?

Muscle-related endpoints in secretagogue research generally follow the growth hormone/IGF-1 axis: receptor activation at the pituitary increases endogenous growth hormone output, hepatic IGF-1 rises, and IGF-1 signaling at skeletal muscle is the proximate driver of protein synthesis and satellite cell activity studied in animal models. Hexarelin has also been examined in catabolic and disuse models, where the question is attenuation of loss rather than accretion of mass — a distinction that changes which controls and which measurement intervals are appropriate.

Because lean tissue changes slowly and measurement error in composition assays is non-trivial, well-designed studies prioritize repeated measures with consistent instrumentation. The muscle growth research overview covers which models the literature has actually used and which endpoints were measured, while the body composition tracking guide addresses interval selection and variability.

Comparative data presentation is a separate problem; the research outcomes framework and the post-research analysis guide describe how baseline and endpoint datasets are typically aligned so that normal biological variation is not mistaken for a treatment signal in a small-n experiment.

Does receptor desensitization affect repeated-exposure study designs?

Tachyphylaxis is a well-documented property of GHS-R1a agonists as a class. Continuous or closely spaced receptor stimulation is generally associated with attenuated secretory response over time, attributed to receptor internalization, altered coupling efficiency and feedback inhibition from rising IGF-1 and somatostatin tone. For a laboratory, this matters practically: an experiment that measures response at a late time point in a continuous-exposure model may report a much smaller effect than an acute-exposure model, and the difference is methodological rather than biological contradiction.

This is why most study designs in the published literature are either acute single-exposure challenges or intermittent-exposure schedules with washout intervals, and why reporting the exposure pattern is as important as reporting the result. The rationale behind intermittent versus continuous exposure structures is covered in the repeated-exposure design discussion, while expected feedback-axis behavior is described in the downstream effects overview.

When an expected response fails to appear, desensitization is one of several candidate explanations alongside material degradation and assay timing; the troubleshooting guide and the pre- versus post-exposure comparison framework walk through how those possibilities are separated.

Can Hexarelin be studied alongside other research peptides?

Combination work is common in secretagogue research because the GHS-R1a pathway and the growth hormone-releasing hormone pathway are distinct and have historically been examined together to test for additive or synergistic pituitary responses. That same logic means combination designs carry real interpretive risk: with two active compounds and one shared endpoint, attributing a result to either agent requires arms that isolate each, which many informal study designs omit.

Beyond pituitary pharmacology, there are practical interaction considerations — shared metabolic clearance routes, overlapping effects on glucose handling, and confounding from compounds that influence somatostatin tone. Researchers mapping these should start with the peptide interaction overview and the combination research discussion, which outline which pairings appear in published work and which are purely speculative.

For laboratories already running an established experimental series, adding a second variable mid-study is generally a design error rather than an efficiency gain; the considerations involved are set out in the adding-to-an-existing-stack guide. Where multiple variables are unavoidable, the common mistakes summary covers the controls and documentation that keep a multi-compound dataset interpretable after the fact.

References

Peer-reviewed sources on Hexarelin indexed in PubMed, listed for research context. Real Peptides supplies Hexarelin for laboratory research use only.

1. Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. European journal of medical research, 2023. PMID 37710348. doi:10.1186/s40001-023-01318-w
2. Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. Microvascular research, 2022. PMID 34856183. doi:10.1016/j.mvr.2021.104280
3. Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Drug target insights, 2021. PMID 34871336. doi:10.33393/dti.2021.2347
4. Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity. Pharmaceuticals (Basel, Switzerland), 2021. PMID 34066741. doi:10.3390/ph14050444
5. Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models. Frontiers in physiology, 2021. PMID 35126171. doi:10.3389/fphys.2021.766818
6. Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats. Canadian journal of physiology and pharmacology, 2021. PMID 32893668. doi:10.1139/cjpp-2020-0218
7. Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. PMID 32403043. doi:10.1016/j.biopha.2020.110165
8. Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice. Peptides, 2019. PMID 31386895. doi:10.1016/j.peptides.2019.170122